-transparent.png){kind=logo}
1. The pharmacological properties of RS 23597-190 (3-(piperdine-1-yl)-propyl-4-amino-5-chloro-2-methoxy benzoate hydrochloride) have been studied in vitro and in vivo. 2. RS 23597-190 competitively antagonized 5-HT4 receptor-mediated relaxations of rat, carbachol precontracted oesophageal muscularis mucosae, (pA2 = 7.8 +/- 0.1; Schild slope = 1.2 +/- 0.2). Affinity estimates (-log KB) at 5-HT4 receptors using either renzapride or SC-53116 as agonists yielded a -log KB value of 8.0 +/- 0.01. In contrast, RS 23597-190 failed to antagonize contractile responses to 5-HT of guinea-pig ileal 5-HT3 receptors, even at concentrations up to 10 microM. 3. Increases in short-circuit current, induced by 5-HT, were studied in guinea-pig ileal mucosal sheets. Concentration-response curves to 5-HT were biphasic, with the high potency phase to 5-HT inhibited by RS 23597-190 and mimicked by 5-methoxytryptamine. The -log KB value for RS 23597-190 at the high potency phase was 7.3 confirming that 5-HT4 receptors mediated the high potency phase. 4. In rat isolated vagus nerve, 5-HT elicited a slow, maintained depolarization at low concentrations and a rapid, transient depolarization at higher concentrations. The high potency, slow depolarizing phase to 5-HT was abolished selectively in the presence of 1 microM RS 23597-190 and the low potency phase was abolished selectively in the presence of 1 microM ondansetron. These data confirm that 5-HT4 and 5-HT3 receptors mediated slow and fast depolarization responses, respectively. 5. At 5-HT3 binding sites in membranes from NG 108-15 cells, labelled by [3H]-quipazine, RS 23597-190 exhibited an apparent affinity (- log Ki) of 5.7 +/- 0.1. At 5-HT3 receptors in membranes from rat cerebral cortex, labelled by [3H]-RS 42358-197, the apparent affinity (- log Ki) of RS 23597-190 was also 5.7 +/- 0.1. In both studies, Hill coefficients were not significantly different from unity. At 5-HT1A, 5-HT2,muscarinic M1, M2, M3, M4 and dopamine D1 and D2 receptors, RS 23597-190 exhibited low apparent affinities, with all - log Ki values less than 5.5.6. Intravenous infusion of RS 23597-190 in the conscious, restrained rat antagonized the von Bezold Jarisch reflex induced by 2-methyl 5-HT, with an ID50 of 300 microg kg-1 min-1, i.v. In the anaesthetized,bilaterally vagotomized micropig, RS 23597-190 (6 mg kg-1, i.v.) antagonized 5-HT-induced tachycardia with a half-life of 77 (63-99) min. Transient arrhythmic effects were noted after administration of the compound.7. In conclusion, RS 23597-190 acts as a high affinity, selective competitive antagonist at 5-HT4 receptors. Thus, the compound appears to be a useful tool for 5-HT4 receptor identification in vitro. In vivo, the compound is rapidly metabolized in pigs such that 5-HT4 blockade is not maintained. However,in the rat, when given by infusion, RS 23597-190 antagonizes 5-HT3 mediated responses, at doses consistent with a low affinity 5-HT3 receptor. These data suggest that, under appropriate experimental conditions, RS 23597-190 may also be used in vivo to characterize further 5-HT4 receptor function.
R M Eglen, and
K Bley, and
D W Bonhaus, and
R D Clark, and
S S Hegde, and
L G Johnson, and
E Leung, and
E H Wong
July 1995,
British journal of pharmacology,
R M Eglen, and
K Bley, and
D W Bonhaus, and
R D Clark, and
S S Hegde, and
L G Johnson, and
E Leung, and
E H Wong
May 1994,
Naunyn-Schmiedeberg's archives of pharmacology,
R M Eglen, and
K Bley, and
D W Bonhaus, and
R D Clark, and
S S Hegde, and
L G Johnson, and
E Leung, and
E H Wong
January 1996,
Behavioural brain research,
R M Eglen, and
K Bley, and
D W Bonhaus, and
R D Clark, and
S S Hegde, and
L G Johnson, and
E Leung, and
E H Wong
July 1994,
British journal of pharmacology,
R M Eglen, and
K Bley, and
D W Bonhaus, and
R D Clark, and
S S Hegde, and
L G Johnson, and
E Leung, and
E H Wong
November 2004,
British journal of pharmacology,
R M Eglen, and
K Bley, and
D W Bonhaus, and
R D Clark, and
S S Hegde, and
L G Johnson, and
E Leung, and
E H Wong
January 1997,
Neuropharmacology,
R M Eglen, and
K Bley, and
D W Bonhaus, and
R D Clark, and
S S Hegde, and
L G Johnson, and
E Leung, and
E H Wong
November 1996,
British journal of pharmacology,
R M Eglen, and
K Bley, and
D W Bonhaus, and
R D Clark, and
S S Hegde, and
L G Johnson, and
E Leung, and
E H Wong
November 2005,
Bioorganic & medicinal chemistry letters,
R M Eglen, and
K Bley, and
D W Bonhaus, and
R D Clark, and
S S Hegde, and
L G Johnson, and
E Leung, and
E H Wong
January 1994,
British journal of pharmacology,
R M Eglen, and
K Bley, and
D W Bonhaus, and
R D Clark, and
S S Hegde, and
L G Johnson, and
E Leung, and
E H Wong
August 1995,
British journal of pharmacology,
